New Report Just Published: World Hepatitis C Virus And Therapeutics Market Report
...bott Diagnostics, Achillion Pharmaceuticals, Inc., anadys Pharmaceuticals, Inc., Boehringer Ingelheim GmbH, ...agnostics Rights from Siemens Healthcare II-63 anadys Secures FDA Fast Track Designation for its Lead Dr...cation for Novel Hepatitis C to with FDA II-68 anadys Discontinues ANA975 II-68 Cerus Bags NIH Fundi...Anadys Pharmaceuticals, Inc. Announces Pricing of Common Stock and Warrant Offering
...e sale of shares of its common stock and warrants. anadys estimates that net proceeds from the offering will... related expenses payable to the placement agent). anadys has entered into subscription agreements with each...er, solicitation or sale is unlawful. About anadys ...Anadys Pharmaceuticals to Present at the Citi Biotech Day
... SAN DIEGO, March 25 /PRNewswire-FirstCall/ -- anadys Pharmaceuticals, Inc. (Nasdaq: ANDS ) announced ...ive Officer of Anadys, will provide an overview of anadys and an update on its ANA598 clinical program in he...l be available through April 15, 2009. About anadys ...Anadys Pharmaceuticals Reports Fourth Quarter and Year-End 2008 Financial Results and Highlights
... SAN DIEGO, Feb. 26 /PRNewswire-FirstCall/ -- anadys Pharmaceuticals, Inc. (Nasdaq: ANDS ), a clinica...3. For the twelve months ended December 31, 2008, anadys reported a net loss of $32.4 million, compared to ...onal oral non-nucleoside polymerase inhibitor that anadys is developing for the treatment of chronic hepatit...Anadys Pharmaceuticals to Report Fourth Quarter and Year End 2008 Financial Results
... SAN DIEGO, Feb. 19 /PRNewswire-FirstCall/ -- anadys Pharmaceuticals, Inc. (Nasdaq: ANDS ) announced ...2009, after the U.S. financial markets close. anadys will hold a conference call and webcast to discuss...l be available through March 12, 2009. About anadys ...Anadys Pharmaceuticals to Present at the BIO CEO & Investor Conference
... SAN DIEGO, Feb. 2 /PRNewswire-FirstCall/ -- anadys Pharmaceuticals, Inc. (Nasdaq: ANDS ) announced ...ive Officer of Anadys, will provide an overview of anadys and an update on its clinical programs: ANA598 an...e available through February 23, 2009. About anadys ...Anadys Pharmaceuticals Commences Dosing ANA598 in Hepatitis C Patients in Phase Ib Study
... SAN DIEGO, Oct. 28 /PRNewswire-FirstCall/ -- anadys Pharmaceuticals, Inc. (Nasdaq: ANDS ) announced t...nding doses of ANA598 over a period of three days. anadys expects to enroll approximately 30 patients in the...om all three cohorts in the first quarter of 2009. anadys may elect to explore other dose levels of ANA598 a...Anadys Pharmaceuticals to Present at Bio Investor Forum
... SAN DIEGO, Oct. 27 /PRNewswire-FirstCall/ -- anadys Pharmaceuticals, Inc. (Nasdaq: ANDS ) announced t...ive Officer of Anadys, will present an overview of anadys and an update on its development programs. The p...ilable through November 13, 2008. About Anadys anadys Pharmaceuticals, Inc. is a clinical-stage biopharm...Isis Reports Financial Results and Highlights for Fiscal year 2007
... as President and Chief Executive Officer of Regulus. Dr. Xanthopoulos is the co-founder and former President and Chief Executive Officer of anadys Pharmaceuticals, Inc. * Peter S. Linsley, Ph.D., was appointed as Chief Scientific Officer of Regulus. Dr. Linsley was Executive Directo...Anadys Pharmaceuticals to Present at BIO InvestorForum 2007
... SAN DIEGO, Oct. 3 /PRNewswire-FirstCall/ -- anadys Pharmaceuticals, Inc. (Nasdaq: ANDS ) announced t... Pharmaceuticals, Inc. will present an overview of anadys and an update on its two development-stage product...nd will be archived until October 24, 2007. About anadys ...ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients
... SAN DIEGO, Jan. 8 /PRNewswire-FirstCall/ -- anadys Pharmaceuticals, Inc. (Nasdaq: ANDS ) today anno...d in the second cohort (400 mg bid) of the study. anadys expects to report detailed data from multiple coho...h other anti-HCV agents." About ANA598 anadys retains worldwide rights to ANA598, which was full...Anadys Pharmaceuticals to Present at the JMP Securities Healthcare Focus Conference
... SAN DIEGO, Sept. 30 /PRNewswire-FirstCall/ -- anadys Pharmaceuticals, Inc. (Nasdaq: ANDS ) announced t...ive Officer of Anadys, will present an overview of anadys and its three clinical programs: ANA598 and ANA773...ailable through October 21, 2008. About Anadys anadys Pharmaceuticals, Inc. is a clinical-stage biopharm...Anadys Pharmaceuticals Resumes Clinical Investigation of TLR7 Mechanism in HCV
... PDT SAN DIEGO, July 7 /PRNewswire-FirstCall/ -- anadys Pharmaceuticals, Inc. (Nasdaq: ANDS ) announced t...ery-other-day dosing over 28 days in HCV patients. anadys also continues to enroll patients in a separate Ph...elopment of ANA975. Webcast of Conference Call anadys will host a conference call today, July 7, 2008 at...Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598
...is C SAN DIEGO, June 2 /PRNewswire-FirstCall/ -- anadys Pharmaceuticals, Inc. (Nasdaq: ANDS ) announced t...cessful completion of the healthy volunteer study, anadys plans to begin a Phase Ib study of ANA598 in HCV-i...nts in February and this study of ANA598 underway, anadys is now focused on achieving important clinical mil...Anadys Pharmaceuticals to Present at the Roth OC Growth Stock Conference
... SAN DIEGO, Feb. 9 /PRNewswire-FirstCall/ -- anadys Pharmaceuticals, Inc. (Nasdaq: ANDS ) announced ...ive Officer of Anadys, will provide an overview of anadys and its clinical programs: ANA598 and ANA773 in he...ll be available through March 2, 2009. About anadys ...Anadys Pharmaceuticals Reports Second Quarter 2009 Financial Results and Program Highlights
... SAN DIEGO, July 30 /PRNewswire-FirstCall/ -- anadys Pharmaceuticals, Inc. (Nasdaq: ANDS ), a biophar...ly. For the six months ended June 30, 2009, anadys reported a net loss of $15.3 million, compared to ...osed Registered Direct Financing. In early June, anadys closed a "registered direct" offering through the ...Anadys Pharmaceuticals to Report Second Quarter 2009 Financial Results
... SAN DIEGO, July 23 /PRNewswire-FirstCall/ -- anadys Pharmaceuticals, Inc. (Nasdaq: ANDS ) announced ..., after the U.S. financial markets close. anadys will hold a conference call and webcast on Thursda...available through August 13, 2009. About anadys ...Anadys Pharmaceuticals Reports First Quarter 2009 Financial Results and Highlights
... SAN DIEGO, April 23 /PRNewswire-FirstCall/ -- anadys Pharmaceuticals, Inc. (Nasdaq: ANDS ), a biophar...onal oral non-nucleoside polymerase inhibitor that anadys is developing for the treatment of chronic hepatit...Potent Antiviral Activity in HCV. Earlier today, anadys presented antiviral and safety data from all three...Anadys Pharmaceuticals to Report First Quarter 2009 Financial Results
... SAN DIEGO, April 17 /PRNewswire-FirstCall/ -- anadys Pharmaceuticals, Inc. (Nasdaq: ANDS ) announced ...2009, after the U.S. financial markets close. anadys will hold a conference call and webcast on Thursda...will be available through May 7, 2009. About anadys ...Anadys Pharmaceuticals to Present at Future Leaders in the Biotech Industry
... SAN DIEGO, March 26 /PRNewswire-FirstCall/ -- anadys Pharmaceuticals, Inc. (Nasdaq: ANDS ) announced ...ive Officer of Anadys, will provide an overview of anadys and its clinical programs: ANA598 and ANA773 in he...l be available through April 16, 2009. About anadys ...Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
... SAN DIEGO, Nov. 25 /PRNewswire-FirstCall/ -- anadys Pharmaceuticals, Inc. (Nasdaq: ANDS ) announced ...ive Officer of Anadys, will provide an overview of anadys and its three clinical programs: ANA598 and ANA77...ailable through December 17, 2008. About anadys ...Anadys Pharmaceuticals to Present at the Needham Focus on Infectious Disease Conference
... SAN DIEGO, Nov. 13 /PRNewswire-FirstCall/ -- anadys Pharmaceuticals, Inc. (Nasdaq: ANDS ) announced t...ive Officer of Anadys, will present an overview of anadys and its three clinical programs: ANA598 and ANA773...ailable through December 4, 2008. About Anadys anadys Pharmaceuticals, Inc. is a clinical-stage biopharm...